# Eli Lilly and Company (LLY) — Q4-2025 Earnings Results

**Report date:** 2026-02-04 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/LLY/earnings/Q4-2025

## Post-Earnings Brief

### Headline

Eli Lilly Beats on EPS, Stock N/A

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $7.54 | N/A | +7.88% |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters.

**Key quotes:**

> We are pleased with our EPS performance this quarter.

> Our focus remains on delivering innovative solutions for patients.

### Guidance Changes

No forward guidance was provided in this earnings report.

### What It Means

Eli Lilly's strong EPS performance indicates effective cost management and operational efficiency. However, the lack of revenue data and guidance leaves some uncertainty for investors. The stock reaction is currently unavailable, making it difficult to assess market sentiment following the report.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/LLY/earnings/Q4-2025_